TITLE

Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

PUB. DATE
January 2004
SOURCE
Cardiovascular Diabetology;2004, Vol. 3, p8
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response. Methods: Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6-3.9 mM/l and HDL cholesterol ⩽ 1.05 mM/l for women and ⩽ 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline. Results: After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m²) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs - 10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate. Conclusions: Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated.
ACCESSION #
28683683

 

Related Articles

  • Vitamin offers lipid treatment hope.  // GP: General Practitioner;4/10/2009, p10 

    The article focuses on the therapeutic effect of vitamin B3 or niacin as a new lipid drug in lowering triglyceride, fatty acid and low-density lipoprotein cholesterol levels, and increase high-density lipoprotein levels. It notes that researchers investigate its molecular pathways and found that...

  • Lipoprotein heterogeneity in persons with Spinal Cord Injury: a model of prolonged sitting and restricted physical activity. La Fountaine, Michael F.; Cirnigliaro, Christopher M.; Emmons, Racine R.; Kirshblum, Steven C.; Galea, Marinella; Spungen, Ann M.; Bauman, William A. // Lipids in Health & Disease;Jul2015, Vol. 14 Issue 1, p1 

    Background: Persons with spinal cord injury (SCI) often have low levels of physical activity, which predispose to increased adiposity and decreased high density lipoprotein cholesterol (HDL-C) concentrations, and, generally, normal low density lipoprotein cholesterol (LDL-C) concentrations. In...

  • Clinical: The Basics - Understanding hypercholesterolaemia. Brown, Harry // GP: General Practitioner;10/22/2010, p34 

    The article discusses various risk factors and treatment of the cardiovascular diseases. It informs that hypercholesterolaemia leads to cardiovascular disorder . It also informs that cardiovascular disease can be prevented by lowering lipids or cholesterol intake in diet. It further informs that...

  • Lipid re-screening: what is the best measure and interval? Takahashi, Osamu; Glasziou, Paul P.; Perera, Rafael; Shimbo, Takuro; Suwa, Jiro; Hiramatsu, Sonoe; Fukui, Tsuguya // Heart;Mar2010, Vol. 96 Issue 6, p448 

    Objectives To estimate the long-term true change variation ('signal') and short-term within-person variation ('noise') of the different lipid measures and evaluate the best measure and the optimal interval for lipid re-screening. Design Retrospective cohort study from 2005 to 2008. Setting A...

  • IMPROVE-IT Findings. Rizzo, Toni; Giugliano, Robert P.; Blazing, Michael A. // MD Conference Express;Oct2015, Vol. 15 Issue 28, p21 

    The IMPROVE-IT trial showed that the cholesterol-lowering drug ezetimibe, when added to simvastatin, provides greater improvement in cardiovascular outcomes among patients with diabetes vs those without diabetes in a population with acute coronary syndrome. Additionally, the rate of new-onset...

  • Evaluation of Lipid Metabolism among Sudanese Patients with Type 2 Diabetes Mellitus. Mustafa Elfaki, Elyasa; Mohamed Abdul Raheem, Esam; Eldeen Ahmed, Seif // International Journal of Pure & Applied Sciences & Technology;Jul2014, Vol. 23 Issue 1, p28 

    There are few researchers who have reported high levels of total cholesterol, LDL, and triglyceride with high HbA1c concentrations in diabetic patients. This was a quantitative, descriptive, analytic, case-control and hospital-based study aimed to evaluate the lipid metabolism among Sudanese...

  • Clinical Utility of Low-Density Lipoprotein Particles and Apolipoprotein B in Patients with Cardiovascular Risk. Ennis, Jennifer L.; Cromwell, William C. // Journal of Family Practice;Jul2013 Supplement, p1 

    The article focuses on the clinical use of low-density lipoprotein (LDL) particles and apolipoprotein B in cardiovascular risk patients. It presents strategies to incorporate LDL-P into the practice and assess treatment options to reach recommended targets of therapy. It mentions that common...

  • Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. Villeneuve, Sylvia; Brisson, Diane; Gaudet, Daniel // Journal of Lipids;10/28/2015, p1 

    Background. Apolipoprotein (Apo) E plays a key role in the handling of lipoprotein particles with ApoE2 and ApoE4 frequently having opposite effects compared to ApoE3. Some individuals simultaneously carry both E2 and E4 alleles. The impact of the ApoE2/4 genotype on lipid concentrations and its...

  • High-Density Lipoprotein as a Therapeutic Target: Treatment Strategies. Chowdhury, M. A. U.; Ali, S. Y.; Rahman, M. M.; Islam, A. E. M. M.; Islam, A. K. M. M. // Cardiovascular Journal;Jul2012, Vol. 5 Issue 1, p73 

    Coronary artery disease (CAD) is one of the most important causes of morbidity and mortality worldwide despite considerable therapeutic advances that control the risk factors. Numerous clinical trials have shown an inverse association between high density lipoprotein cholesterol levels and the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics